172 related articles for article (PubMed ID: 22417857)
61. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
62. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
[TBL] [Abstract][Full Text] [Related]
63. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer.
Al-Khattabi H; Kelany A; Buhmeida A; Al-Maghrabi J; Lari S; Chaudhary A; Gari M; Abuzenadah A; Al-Qahtani M
Anticancer Res; 2010 Oct; 30(10):4081-8. PubMed ID: 21036723
[TBL] [Abstract][Full Text] [Related]
65. Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study.
Ugiagbe EE; Olu-Eddo AN; Obaseki DE
Niger J Clin Pract; 2011; 14(3):332-7. PubMed ID: 22037080
[TBL] [Abstract][Full Text] [Related]
66. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
67. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
Mrhalova M; Kodet R
J Cancer Res Clin Oncol; 2007 May; 133(5):321-9. PubMed ID: 17165026
[TBL] [Abstract][Full Text] [Related]
68. Her-2/neu evaluation in Sister Mary Joseph's nodule from breast carcinoma: a case report and review of the literature.
Brunelli M; Manfrin E; Miller K; Eccher A; Gobbo S; Reghellin D; Chilosi M; Remo A; Martignoni G; Menestrina F; Bonetti F
J Cutan Pathol; 2009 Jun; 36(6):702-5. PubMed ID: 19515052
[TBL] [Abstract][Full Text] [Related]
69. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
70. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
Johnson CJ; Barry MB; Vasef MA; Deyoung BR
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):54-8. PubMed ID: 18091319
[TBL] [Abstract][Full Text] [Related]
71. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.
Safran H; Steinhoff M; Mangray S; Rathore R; King TC; Chai L; Berzein K; Moore T; Iannitti D; Reiss P; Pasquariello T; Akerman P; Quirk D; Mass R; Goldstein L; Tantravahi U
Am J Clin Oncol; 2001 Oct; 24(5):496-9. PubMed ID: 11586103
[TBL] [Abstract][Full Text] [Related]
72. High-level detection of gene amplification and chromosome aneuploidy in extracted nuclei from paraffin-embedded tissue of human cancer using FISH: a new approach for retrospective studies.
Rossi E; Ubiali A; Balzarini P; Cadei M; Alpi F; Grigolatoi PG
Eur J Histochem; 2005; 49(1):53-8. PubMed ID: 15823795
[TBL] [Abstract][Full Text] [Related]
73. Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.
Xian ZH; Zhang SH; Cong WM; Wu WQ; Wu MC
J Clin Pathol; 2005 May; 58(5):500-3. PubMed ID: 15858121
[TBL] [Abstract][Full Text] [Related]
74. Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen Dual Color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: a multicenter clinical validation study.
Masood S; Bui MM; Yung JF; Mark HF; Wong EY; Birkmeier JM; Yang SJ; Hsu P
Ann Clin Lab Sci; 1998; 28(4):215-23. PubMed ID: 9715348
[TBL] [Abstract][Full Text] [Related]
75. Her-2/neu amplification determined by real-time quantitative PCR and its association with clinical outcome of breast cancer in Thailand.
Chariyalertsak S; Purisa W; Vinyuvat S
Asian Pac J Cancer Prev; 2011; 12(7):1703-6. PubMed ID: 22126548
[TBL] [Abstract][Full Text] [Related]
76. HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components.
Andersson J; Linderholm B; Bergh J; Elmberger G
Appl Immunohistochem Mol Morphol; 2004 Mar; 12(1):14-20. PubMed ID: 15163013
[TBL] [Abstract][Full Text] [Related]
77. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing.
Cell Markers And Cytogenetics Committees College Of American Pathologists
Arch Pathol Lab Med; 2002 Jul; 126(7):803-8. PubMed ID: 12088449
[TBL] [Abstract][Full Text] [Related]
78. Expression of HER-2/neu in Oral Squamous Cell Carcinoma.
Mirza S; Hadi N; Pervaiz S; Zeb Khan S; Mokeem SA; Abduljabbar T; Al-Hamoudi N; Vohra F
Asian Pac J Cancer Prev; 2020 May; 21(5):1465-1470. PubMed ID: 32458657
[TBL] [Abstract][Full Text] [Related]
79. Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors.
Azzoni C; Bottarelli L; Cecchini S; Lagrasta C; Pizzi S; D'Adda T; Tamburini E; Rindi G; Bordi C
Virchows Arch; 2011 May; 458(5):525-36. PubMed ID: 21445634
[TBL] [Abstract][Full Text] [Related]
80. Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
Yaziji H; Gown AM
Adv Anat Pathol; 2002 Nov; 9(6):338-44. PubMed ID: 12409642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
